Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6
G.R. Vanaja, Hemalatha Golaconda Ramulu, Arunasree M. Kalle
Cell Communication and Signaling (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Yuan Cheng, He Cai, Manni Wang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 891
Modulation of cellular processes by histone and non-histone protein acetylation
Maria Shvedunova, Asifa Akhtar
Nature Reviews Molecular Cell Biology (2022) Vol. 23, Iss. 5, pp. 329-349
Closed Access | Times Cited: 519
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Lourdes Hontecillas‐Prieto, Rocío Flores-Campos, Andrew Silver, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 142
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik, Sara Moufarrij, Alejandro Villagra
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2241-2241
Open Access | Times Cited: 109
Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
Fraidoon Kavoosi, Masumeh Sanaei
Advanced Biomedical Research (2019) Vol. 8, Iss. 1, pp. 63-63
Open Access | Times Cited: 101
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics
Yang Zhang, Jun Ying, Jia Jun Hong, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 5, pp. 2467-2480
Closed Access | Times Cited: 89
Pathological Role of HDAC8: Cancer and Beyond
Ji Yoon Kim, Hayoung Cho, Jung Yoo, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3161-3161
Open Access | Times Cited: 49
Role of histone deacetylases and their inhibitors in neurological diseases
Liying Zhang, Sen-Yu Zhang, Ri Wen, et al.
Pharmacological Research (2024), pp. 107410-107410
Open Access | Times Cited: 16
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
Medical Oncology (2024) Vol. 41, Iss. 4
Closed Access | Times Cited: 11
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Rihan Hai, Liuer He, Guang Shu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 47
Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy
Xin Sun, Yuhan Shu, Guiqin Ye, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 2, pp. 838-852
Open Access | Times Cited: 44
Traditional Patchouli essential oil modulates the host’s immune responses and gut microbiota and exhibits potent anti-cancer effects in Apc mice
Wai Yie Leong, Guoxin Huang, Weilin Liao, et al.
Pharmacological Research (2022) Vol. 176, pp. 106082-106082
Closed Access | Times Cited: 33
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 30
Histone deacetylase 8 inhibition prevents the progression of peritoneal fibrosis by counteracting the epithelial-mesenchymal transition and blockade of M2 macrophage polarization
Xun Zhou, Hui Chen, Yingfeng Shi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation‐Mediated c‐Myc Deubiquitylation to Facilitate Mutant TP53 Transcription
Z.H Wang, Yaming Li, H. J. Yang, et al.
Advanced Science (2024)
Open Access | Times Cited: 7
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
Zhicheng Gu, Shuxian Lin, Junhui Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116571-116571
Closed Access | Times Cited: 6
Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
Kelly N. Hassell
Diseases (2019) Vol. 7, Iss. 4, pp. 57-57
Open Access | Times Cited: 53
The function of histone acetylation in cervical cancer development
Shanshan Liu, Weiqin Chang, Yuemei Jin, et al.
Bioscience Reports (2019) Vol. 39, Iss. 4
Open Access | Times Cited: 37
Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus
Natália Lourenço de Freitas, Maria Gabriela Deberaldini, Diana Gomes, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 8
Open Access | Times Cited: 31
Designing HDAC-PROTACs: Lessons Learned So Far
Fabian Fischer, Leandro A. Alves Avelar, Laoise Murray, et al.
Future Medicinal Chemistry (2021) Vol. 14, Iss. 3, pp. 143-166
Open Access | Times Cited: 28
Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability
Stefano Federico, Tuhina Khan, Anna Fontana, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114409-114409
Closed Access | Times Cited: 19
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
Milan Beljkaš, Aleksandra Ilić, Alen Cebzan, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2581-2581
Open Access | Times Cited: 11
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)
Suvankar Banerjee, Balaram Ghosh, Tarun Jha, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 1019-1045
Closed Access | Times Cited: 4
Investigation of All Disease-Relevant Lysine Acetylation Sites in α-Synuclein Enabled by Non-canonical Amino Acid Mutagenesis
Marie Shimogawa, Minghao Li, Grace Park, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
Amrita Ulhe, Prerna Raina, Amol Chaudhary, et al.
Epigenetics (2025) Vol. 20, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top